Fate Therapeutics Net Income
| FATE Stock | USD 1.19 0.02 1.65% |
As of the 30th of January, Fate Therapeutics shows the Mean Deviation of 3.85, standard deviation of 4.8, and Variance of 23.02. Fate Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Fate Therapeutics market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Fate Therapeutics is priced favorably, providing market reflects its regular price of 1.19 per share. Given that Fate Therapeutics is a hitting penny stock territory we advise to closely look at its jensen alpha.
Fate Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 0.6382 | Revenue | Earnings Share (1.33) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -167.6 M | -159.3 M | |
| Net Loss | -167.6 M | -176 M | |
| Net Loss | -253.5 M | -240.9 M | |
| Net Loss | (1.88) | (1.98) |
Fate | Net Income | Build AI portfolio with Fate Stock |
Analyzing Fate Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Fate Therapeutics's current valuation and future prospects.
Latest Fate Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Fate Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Fate Therapeutics financial statement analysis. It represents the amount of money remaining after all of Fate Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Fate Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fate Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (186.26 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Fate Net Income Regression Statistics
| Arithmetic Mean | (98,452,754) | |
| Coefficient Of Variation | (83.84) | |
| Mean Deviation | 73,588,769 | |
| Median | (66,598,000) | |
| Standard Deviation | 82,538,621 | |
| Sample Variance | 6812.6T | |
| Range | 241.6M | |
| R-Value | (0.87) | |
| Mean Square Error | 1814.3T | |
| R-Squared | 0.75 | |
| Slope | (14,158,337) | |
| Total Sum of Squares | 109002T |
Fate Net Income History
Other Fundumenentals of Fate Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Fate Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Fate Therapeutics is extremely important. It helps to project a fair market value of Fate Stock properly, considering its historical fundamentals such as Net Income. Since Fate Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fate Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fate Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Fate diversify its offerings? Factors like these will boost the valuation of Fate Therapeutics. Market participants price Fate higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fate Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.33) | Revenue Per Share | Quarterly Revenue Growth (0.43) | Return On Assets | Return On Equity |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fate Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Fate Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Fate Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Fate Therapeutics.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Fate Therapeutics on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Fate Therapeutics or generate 0.0% return on investment in Fate Therapeutics over 90 days. Fate Therapeutics is related to or competes with Nkarta, Alector, Vor Biopharma, Cassava Sciences, Prelude Therapeutics, Inovio Pharmaceuticals, and PepGen. Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for ca... More
Fate Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Fate Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Fate Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 20.97 | |||
| Value At Risk | (7.63) | |||
| Potential Upside | 7.27 |
Fate Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fate Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Fate Therapeutics' standard deviation. In reality, there are many statistical measures that can use Fate Therapeutics historical prices to predict the future Fate Therapeutics' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.48) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.23) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Fate Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Fate Therapeutics January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 3.85 | |||
| Coefficient Of Variation | (1,260) | |||
| Standard Deviation | 4.8 | |||
| Variance | 23.02 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.48) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 20.97 | |||
| Value At Risk | (7.63) | |||
| Potential Upside | 7.27 | |||
| Skewness | 0.2548 | |||
| Kurtosis | 0.0264 |
Fate Therapeutics Backtested Returns
At this point, Fate Therapeutics is very risky. Fate Therapeutics secures Sharpe Ratio (or Efficiency) of close to zero, which denotes the company had a close to zero % return per unit of risk over the last 3 months. We have found twenty-one technical indicators for Fate Therapeutics, which you can use to evaluate the volatility of the firm. Please confirm Fate Therapeutics' Standard Deviation of 4.8, variance of 23.02, and Mean Deviation of 3.85 to check if the risk estimate we provide is consistent with the expected return of 0.0101%. The firm shows a Beta (market volatility) of 1.69, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Fate Therapeutics will likely underperform. Fate Therapeutics right now shows a risk of 4.61%. Please confirm Fate Therapeutics jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Fate Therapeutics will be following its price patterns.
Auto-correlation | 0.34 |
Below average predictability
Fate Therapeutics has below average predictability. Overlapping area represents the amount of predictability between Fate Therapeutics time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Fate Therapeutics price movement. The serial correlation of 0.34 indicates that nearly 34.0% of current Fate Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.34 | |
| Spearman Rank Test | 0.17 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Fate Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Fate Therapeutics reported net income of (186.26 Million). This is 154.58% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 132.62% higher than that of the company.
Fate Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fate Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fate Therapeutics could also be used in its relative valuation, which is a method of valuing Fate Therapeutics by comparing valuation metrics of similar companies.Fate Therapeutics is currently under evaluation in net income category among its peers.
Fate Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Fate Therapeutics from analyzing Fate Therapeutics' financial statements. These drivers represent accounts that assess Fate Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Fate Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 5.5B | 977.0M | 368.1M | 187.6M | 168.8M | 160.4M | |
| Enterprise Value | 5.5B | 1.0B | 429.7M | 236.8M | 213.1M | 202.5M |
Fate Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Fate Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Fate Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Fate Therapeutics' value.| Shares | State Street Corp | 2025-06-30 | 2.2 M | Citigroup Inc | 2025-06-30 | 1.9 M | Tang Capital Management Llc | 2025-06-30 | 1.9 M | Jacobs Levy Equity Management, Inc. | 2025-06-30 | 1.2 M | Ubs Group Ag | 2025-06-30 | 962.7 K | Schonfeld Strategic Advisors Llc | 2025-06-30 | 930.8 K | Millennium Management Llc | 2025-06-30 | 879.7 K | Aqr Capital Management Llc | 2025-06-30 | 846.2 K | Northern Trust Corp | 2025-06-30 | 844.4 K | Redmile Group, Llc | 2025-06-30 | 12.9 M | Blackrock Inc | 2025-06-30 | 10.8 M |
Fate Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (19.95) % | ||||
| Current Valuation | 4.55 M | ||||
| Shares Outstanding | 115.35 M | ||||
| Shares Owned By Insiders | 1.90 % | ||||
| Shares Owned By Institutions | 79.28 % | ||||
| Number Of Shares Shorted | 11.44 M | ||||
| Price To Earning | (4.35) X | ||||
| Price To Book | 0.60 X | ||||
| Price To Sales | 19.23 X | ||||
| Revenue | 13.63 M | ||||
| Gross Profit | (92.41 M) | ||||
| EBITDA | (176.58 M) | ||||
| Net Income | (186.26 M) | ||||
| Cash And Equivalents | 568.85 M | ||||
| Cash Per Share | 5.86 X | ||||
| Total Debt | 85.27 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 6.55 X | ||||
| Book Value Per Share | 2.03 X | ||||
| Cash Flow From Operations | (122.87 M) | ||||
| Short Ratio | 7.37 X | ||||
| Earnings Per Share | (1.33) X | ||||
| Target Price | 4.94 | ||||
| Number Of Employees | 181 | ||||
| Beta | 2.23 | ||||
| Market Capitalization | 137.27 M | ||||
| Total Asset | 440.69 M | ||||
| Retained Earnings | (1.4 B) | ||||
| Working Capital | 253.39 M | ||||
| Current Asset | 47.4 M | ||||
| Current Liabilities | 14.68 M | ||||
| Net Asset | 440.69 M |
About Fate Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fate Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fate Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fate Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Check out For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Will Biotechnology sector continue expanding? Could Fate diversify its offerings? Factors like these will boost the valuation of Fate Therapeutics. Market participants price Fate higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fate Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.33) | Revenue Per Share | Quarterly Revenue Growth (0.43) | Return On Assets | Return On Equity |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fate Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.